A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
第2相
完了
NCT04526899
| 対象疾患 | Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma |
|---|
| 相 | 第2相 |
|---|
| スポンサー | BioNTech SE |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 184 名 |
|---|
| 介入（薬剤） | BNT111, Cemiplimab |
|---|
| 開始日 | 2021年5月19日 |
|---|
| 完了日 | 2024年1月25日 |
|---|
| 結果公開日 | 2025年12月15日 |
|---|
概要
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. Patients will be randomized in a 2:1:1 ratio to Arm 1 (BNT111 + cemiplimab) and calibrator Arm 2 (BNT111 monotherapy), and Arm 3 (cemiplimab monotherapy). Patients in single agent calibrator arms (Arms 2 and 3), who experience centrally verified disease progression under single agent treatment, may be offered addition of the other compound to the ongoing treatment after re-consent.
Arm 1: Objective Response Rate (ORR)
Up to 24 months · percentage of participants
| Arm 1: BNT111 + Cemiplimab | 18.0 percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。